Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Hypertension With Overweight or Obesity

In brief

The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;

Key facts

Study ID

NCT07528027

Run by

Shandong Suncadia Medicine Co., Ltd.

People needed

648

Starts

2026-05-29

Expected to finish

2028-01-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• On the day of signing the informed consent form, the age should be between 18 and 70 years old, with no gender restrictions;
• When screening or randomizing, the average office blood pressure meets any of the following conditions: ① 140 mmHg ≤ SBP < 170 mmHg, and DBP < 110 mmHg; ② 90 mmHg ≤ DBP < 110 mmHg, and 130 mmHg ≤ SBP < 170 mmHg;
• Patients with untreated hypertension, or those who have received stable doses of any or all of the following classes of antihypertensive medications within 30 days prior to screening: 1) angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), 2) thiazides and thiazide-like diuretics, 3) calcium channel blockers. Patients who are currently receiving stable doses of beta blockers (such as metoprolol or atenolol) or mineralocorticoid receptor antagonists (such as spironolactone) and intend to continue these treatments at their current doses may be included in this study;
• During screening, BMI should be ≥24 kg/m2;

You may not qualify if…

• Having a known secondary cause of hypertension
• History of previously diagnosed heart failure with reduced ejection fraction (HFrEF);
• Those who have undergone coronary revascularization within the previous 90 days or plan to undergo it during the trial period;
• Diagnosed or suspected with type 1 diabetes, special type of diabetes, or secondary diabetes (excluding gestational diabetes);
• History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/requiring treatment of gallbladder disease (excluding those who have undergone cholecystectomy but are still eligible for enrollment as determined by the investigator);

Where it is running

• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)
• The First Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.